882188-88-7

Usage

Uses

1H-Indazole-1-carboxylic acid, 3-formyl-, 1,1-dimethylethyl ester is used as a chemical intermediate for the synthesis of various organic compounds in the chemical industry. Its ester and formyl functional groups make it a versatile building block for the creation of more complex molecules, which can be utilized in a wide range of applications.
Used in Pharmaceutical Research:
1H-Indazole-1-carboxylic acid, 3-formyl-, 1,1-dimethylethyl ester is used as a starting material for the development of new pharmaceutical compounds. Its unique structure and functional groups can be exploited to design and synthesize novel drug candidates with potential therapeutic applications.
Used in Material Science:
1H-Indazole-1-carboxylic acid, 3-formyl-, 1,1-dimethylethyl ester is used as a component in the development of new materials with specific properties. Its incorporation into polymers or other materials can lead to the creation of materials with tailored characteristics, such as improved stability, enhanced reactivity, or unique optical properties.
Used in Agricultural Chemistry:
1H-Indazole-1-carboxylic acid, 3-formyl-, 1,1-dimethylethyl ester is used as a precursor in the synthesis of agrochemicals, such as pesticides or herbicides. Its chemical properties can be harnessed to create new compounds with increased efficacy and reduced environmental impact.
Used in Dye and Pigment Industry:
1H-Indazole-1-carboxylic acid, 3-formyl-, 1,1-dimethylethyl ester is used as a building block for the production of dyes and pigments. Its aromatic structure and functional groups can contribute to the development of new colorants with improved color strength, stability, and application properties.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 5235-10-9 1H-indazole-3-carboxaldehyde 
• 4498-67-3 1H-Indazole-3-carboxylic acid 
• 64132-13-4 3-(hydroxymethyl)-1H-indazole 
• 351457-12-0 1H-indazole-3-carboxylic acid methoxy(methyl)amide 
• 882188-87-6 tert-butyl 3-(hydroxymethyl)-1H-indazole-1-carboxylate 

Downstream Products

• 936132-64-8 3-(2-benzyloxycarbonylamino-2-methoxycarbonyl-vinyl)-indazole-1-carboxylic acid tert-butyl ester 
• 1428969-58-7 1-(1H-indazol-3-yl)-2-((3-methoxyphenyl)amino)-2-phenylethanone 

Relevant academic research and scientific papers

GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS

The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

VIRAL REPLICATION INHIBITORS

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

New practical access to 2-azatryptophans and dehydro derivatives via the Wittig-Horner reaction

The Wittig-Horner reaction of protected 3-formylindazoles 1 with (±)-N-(benzyloxycarbonyl)-α-phosphonoglycine trimethyl ester 2 has been developed as a new practical synthesis of dehydro 2-azatryptophans and amino acid derivatives. The preparation of 5-br

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Compounds of Formula I: (I); are HIV reverse transcriptase inhibitors, wherein X, U, V, W, R1, R2, R3, R4, n, p, and q are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Identification of a buried pocket for potent and selective inhibition of Chk1: Prediction and verification

Inhibition of the Chk1 kinase by small molecules binding to its active site is a strategy of great therapeutic interest for oncology. We report how computational modelling predicted the binding mode of ligands of special interest to the Chk1 ATP site, for representatives of an indazole series and debromohymenialdisine. These binding modes were subsequently confirmed by X-ray crystallography. The binding mode of a potent indazole derivative involves non-conventional C-H...O and N-H...π-aromatic interactions with the protein. These interactions are formed in a buried pocket at the periphery of the ATP-binding site, the importance of which has previously been overlooked for ligand design against Chk1. It is demonstrated that filling this pocket can confer ligands with dramatically enhanced affinity for Chk1. Structural arguments in conjunction with assay data explain why targeting this pocket is also advantageous for selective binding to Chk1. Structural overlays of known inhibitors complexed with Chk1 show that only the indazole series utilizes the pocket of interest. Therefore, the analysis presented here should prove helpful in guiding future structure-based ligand design efforts against Chk1.